

ERBB2 & CD3E

Research Grade Runimotamab

Catalog No.	DHC09612A DHC09612B	Quantity:	100 µg 1.0 mg
Alternate Names:	Bispecific, BTRC-4017A, RG-6194, CAS: 2361325-98-4		
Description:	Research Grade Runimotamab is a humanized T-cell dependent bispecific (TDB) monoclonal antibody with potential immunostimulatory and antineoplastic activities. Upon administration, runimotamab possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of runimotamab, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.		
UniProt ID (target):	P04626 & P07766		
Target:	Human HER2 (CD340) and CD3e		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO		
Isotype:	Human IgG1 kappa		
Formulation:	Sterile-filtered 0.01 M PBS, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
INN:	Runimotamab		
Applications:	Functional studies		
Bioactivity:	EC ₅₀ = 46.86 ng/ml by indirect ELISA		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Cell Sciences®
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com